Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression.

Brun R, Naroditsky I, Waterman M, Ben-Izhak O, Groisman G, Ilan N, Vlodavsky I.

Mod Pathol. 2009 Dec;22(12):1548-54. doi: 10.1038/modpathol.2009.115. Epub 2009 Sep 11.

2.

Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.

Ishimura N, Amano Y, Sanchez-Siles AA, Fukuhara H, Takahashi Y, Uno G, Tamagawa Y, Mishima Y, Yuki T, Ishihara S, Kinoshita Y.

J Clin Gastroenterol. 2011 Sep;45(8):665-72. doi: 10.1097/MCG.0b013e318207f240.

PMID:
21325951
3.

Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.

Inge LJ, Fowler AJ, Paquette KM, Richer AL, Tran N, Bremner RM.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):531-8. doi: 10.1016/j.jtcvs.2012.10.041. Epub 2012 Nov 9.

5.

Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.

Scheil-Bertram S, Lorenz D, Ell C, Sheremet E, Fisseler-Eckhoff A.

Mod Pathol. 2008 Aug;21(8):961-7. doi: 10.1038/modpathol.2008.73. Epub 2008 May 23.

7.

Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.

Goodarzi M, Correa AM, Ajani JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM.

Mod Pathol. 2009 Dec;22(12):1612-21. doi: 10.1038/modpathol.2009.133. Epub 2009 Sep 4.

8.

Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.

Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE.

Am J Gastroenterol. 2001 Apr;96(4):990-6.

PMID:
11316217
9.

Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.

Lagorce C, Paraf F, Vidaud D, Couvelard A, Wendum D, Martin A, Fléjou JF.

Histopathology. 2003 May;42(5):457-65.

PMID:
12713622
10.

Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma.

Sonoda R, Naomoto Y, Shirakawa Y, Fujiwara Y, Yamatsuji T, Noma K, Tanabe S, Takaoka M, Gunduz M, Tsujigiwa H, Nagatsuka H, Ohara N, Yoshino T, Takubo K, Vieth M, Tanaka N.

Histopathology. 2010 Jul;57(1):90-100. doi: 10.1111/j.1365-2559.2010.03594.x.

PMID:
20653782
11.

Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.

Halm U, Tannapfel A, Breitung B, Breidert M, Wittekind CW, Mössner J.

Hepatogastroenterology. 2000 Jul-Aug;47(34):962-6.

PMID:
11020858
12.

Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.

Kazeminezhad B, Mirafsharieh SA, Dinyari K, Azizi D, Ebrahimi A.

Turk J Gastroenterol. 2014 Jun;25(3):253-6. doi: 10.5152/tjg.2014.5454.

13.

Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials.

Eisen GM, Montgomery EA, Azumi N, Hartmann DP, Bhargava P, Lippman M, Benjamin SB.

Gastrointest Endosc. 1999 Dec;50(6):814-8.

PMID:
10570342
14.

[Expression and clinical significance of the AgNOR and PCNA in Barrett's adenocarcinoma and its precancerous lesions].

Li H, Yao S, Stuart R.

Zhonghua Zhong Liu Za Zhi. 1995 Jul;17(4):286-8. Chinese.

PMID:
7587897
15.

Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus.

Hong MK, Laskin WB, Herman BE, Johnston MH, Vargo JJ, Steinberg SM, Allegra CJ, Johnston PG.

Cancer. 1995 Jan 15;75(2):423-9.

PMID:
7812911
16.

Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67).

Trakál E, Guidi A, Butti AL, Trakál JJ, Sambuelli R, Zárate FE.

Acta Gastroenterol Latinoam. 2010 Sep;40(3):211-5.

PMID:
21049770
17.

Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.

Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ.

Am J Gastroenterol. 2009 Nov;104(11):2673-80. doi: 10.1038/ajg.2009.437. Epub 2009 Jul 28.

PMID:
19638963
18.

Immunohistochemical presentation in non-malignant and malignant Barrett's epithelium.

Kleeff J, Friess H, Liao Q, Büchler MW.

Dis Esophagus. 2002;15(1):10-5. Review.

PMID:
12060037
19.

Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma.

Brabender J, Lord RV, Wickramasinghe K, Metzger R, Schneider PM, Park JM, Hölscher AH, DeMeester TR, Danenberg KD, Danenberg PV.

J Gastrointest Surg. 2002 May-Jun;6(3):359-67.

PMID:
12022988
20.

The diagnosis and management of Barrett's esophagus.

DeMeester SR, DeMeester TR.

Adv Surg. 1999;33:29-68. Review.

PMID:
10572561

Supplemental Content

Support Center